Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis

AN Abrunhosa-Branquinho; R Bar-Deroma; S Collette; E Clementel; Y Liu; CW Hurkmans; L Feuvret; K van Beek; Martin van den Bent; BG Baumert; DC Weber

doi:10.1016/j.radonc.2018.03.013

Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis

AN Abrunhosa-Branquinho, R Bar-Deroma, S Collette, E Clementel, Y Liu, CW Hurkmans, L Feuvret, K van Beek, Martin van den Bent, BG Baumert, DC Weber

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	292-298
Number of pages	7
Journal	Radiotherapy and Oncology
Volume	127
Issue number	2
DOIs	https://doi.org/10.1016/j.radonc.2018.03.013
Publication status	Published - 2018

Access to Document

10.1016/j.radonc.2018.03.013

http://hdl.handle.net/1765/114037

Cite this

Abrunhosa-Branquinho, AN., Bar-Deroma, R., Collette, S., Clementel, E., Liu, Y., Hurkmans, CW., Feuvret, L., van Beek, K., van den Bent, M., Baumert, BG., & Weber, DC. (2018). Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. Radiotherapy and Oncology, 127(2), 292-298. https://doi.org/10.1016/j.radonc.2018.03.013

Abrunhosa-Branquinho, AN ; Bar-Deroma, R ; Collette, S et al. / Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. In: Radiotherapy and Oncology. 2018 ; Vol. 127, No. 2. pp. 292-298.

@article{842d6ed99ac54383a06d8b8877d130b6,

title = "Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial {"}concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma{"}: Individual case review analysis",

author = "AN Abrunhosa-Branquinho and R Bar-Deroma and S Collette and E Clementel and Y Liu and CW Hurkmans and L Feuvret and {van Beek}, K and {van den Bent}, Martin and BG Baumert and DC Weber",

year = "2018",

doi = "10.1016/j.radonc.2018.03.013",

language = "Undefined/Unknown",

volume = "127",

pages = "292--298",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

Abrunhosa-Branquinho, AN, Bar-Deroma, R, Collette, S, Clementel, E, Liu, Y, Hurkmans, CW, Feuvret, L, van Beek, K, van den Bent, M, Baumert, BG & Weber, DC 2018, 'Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis', Radiotherapy and Oncology, vol. 127, no. 2, pp. 292-298. https://doi.org/10.1016/j.radonc.2018.03.013

Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. / Abrunhosa-Branquinho, AN; Bar-Deroma, R; Collette, S et al.

In: Radiotherapy and Oncology, Vol. 127, No. 2, 2018, p. 292-298.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis

AU - Abrunhosa-Branquinho, AN

AU - Bar-Deroma, R

AU - Collette, S

AU - Clementel, E

AU - Liu, Y

AU - Hurkmans, CW

AU - Feuvret, L

AU - van Beek, K

AU - van den Bent, Martin

AU - Baumert, BG

AU - Weber, DC

PY - 2018

Y1 - 2018

U2 - 10.1016/j.radonc.2018.03.013

DO - 10.1016/j.radonc.2018.03.013

M3 - Article

VL - 127

SP - 292

EP - 298

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 2

ER -

Abrunhosa-Branquinho AN, Bar-Deroma R, Collette S, Clementel E, Liu Y, Hurkmans CW et al. Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. Radiotherapy and Oncology. 2018;127(2):292-298. https://doi.org/10.1016/j.radonc.2018.03.013